Autres langues Avacta Group Plc

Actions

AVCT

GB00BYYW9G87

Recherche biotechnologique et médicale

Marché Fermé - London S.E. Autres places de cotation 17:35:03 15/05/2026			Varia. 5j.	Varia. 1 janv.
86,50 ^GBX	-0,46%		+4,85%	+49,14%

06/05	Avacta Therapeutics présente de nouvelles comparaisons sur la libération de charge utile pre\|CISION face aux ADC approuvés et sur le double vecteur AVA6207	CI
21/04	Vaalco anticipe un reste d'exercice 2026 "très rentable"	AN

Autres langues

06/05	Avacta : presents new comparisons of pre\|CISION® payload release vs approved ADCs and AVA6207 dual payload delivery at Science Day 2026
06/05	Avacta presents new comparisons of pre\|CISION® payload release vs approved ADCs and AVA6207 dual payload delivery at Science Day 2026
06/05	Avacta Therapeutics Presents New Comparisons Of Pre\|CISION Payload Release Versus Approved ADCs And AVA6207 Dual Payload Delivery
21/04	Vaalco says remainder of 2026 to be "very profitable"
21/04	Avacta data at AACR 2026 underline favorable profile of AVA6103 and advantages of pre\|CISION® delivery platform
21/04	Avacta Therapeutics Presents Favorable Data for AVA6103 and Showcases Dual Payload pre\|CISION Platform At AACR 2026
14/04	Avacta CEO Christina Coughlin Named as One of In Vivo's 2026 Rising Leaders
09/04	Somero Enterprises extends buyback to USD6.0 million
09/04	Avacta hails "important milestones" in start of "transformative" year
08/04	Avacta : Announces 2026 Science Day Event
31/03	Avacta announces first patient treated in Phase 1 FOCUS-01 trial of FAP-Exd (AVA6103) - a sustained-release pre\|CISION® exatecan peptide drug conjugate
31/03	Avacta Therapeutics Announces First Patient Treated In Phase 1 Focus-01 Trial Of FAP-Exd
27/03	Avacta Therapeutics Conditionally Raises GBP10 Million via Share Placing, Subscription
27/03	Avacta raises GBP10 million in equity for clinical tests
27/03	Avacta : Results of Oversubscribed Placing and Subscription
27/03	Avacta Therapeutics says placing & subscription represent 3.60% of issued share capital
27/03	Avacta to Raise GBP10 Million via Equity Placing, Subscription
26/03	Avacta Therapeutics proposed placing via accelerated bookbuild & subscription to raise about £10 million
26/03	Avacta : Proposed Placing via an accelerated bookbuild and Subscription to raise approximately £10 million
17/03	Avacta Announces Preclinical and Translational Presentations of pre\|CISION® Platform Candidates at the 2026 AACR Annual Conference
16/03	Avacta opens phase 1 trial for conjugate's efficacy regarding tumours
16/03	Avacta Group announces phase 1 study opening for AVA6103
04/03	Avacta : TD Cowen 46th Annual Healthcare Conference – Presentation slides
04/03	Avacta : Corporate Deck – March 2026
03/03	Avacta : Academy – Episode 2